Yes, that is my opinion. IMO it pretty well proved itself in PH2A and the current test is only showing that the few reactions they had by patients in the prior trials was due to too high a dose. I think B is pretty much a shoo-in for passing all trials with flying colors based on past trials but I have no medical background.
Market Data 
Markets 
AI
